The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Chondroitin for osteoarthritis
Open accessAbstract
BACKGROUND: Osteoarthritis, a common joint disorder, is one of the leading causes of disability. Chondroitin has emerged as a new treatment. Previous meta-analyses have shown contradictory results on the efficacy of chondroitin. This, in addition to the publication of more trials, necessitates a systematic review. OBJECTIVES: To evaluate the benefit and harm of oral chondroitin for treating osteoarthritis compared with placebo or a comparator oral medication including, but not limited to, nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, opioids, and glucosamine or other "herbal" medications. SEARCH METHODS: We searched seven databases up to November 2013, including the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, CINAHL, EMBASE, Science Citation Index (Web of Science) and Current Controlled Trials. We searched the US Food and Drug Administration (FDA) and European Medicines Agency (EMEA) websites for adverse effects. Trial registers were not searched. SELECTION CRITERIA: All randomized or quasi-randomized clinical trials lasting longer than two weeks, studying adults with osteoarthritis in any joint, and comparing chondroitin with placebo, an active control such as NSAIDs, or other "herbal" supplements such as glucosamine. DATA COLLECTION AND ANALYSIS: Two review authors independently performed all title assessments, data extractions, and risk of bias assessments. MAIN RESULTS: Forty-three randomized controlled trials including 4,962 participants treated with chondroitin and 4,148 participants given placebo or another control were included. The majority of trials were in knee OA, with few in hip and hand OA. Trial duration varied from 1 month to 3 years. Participants treated with chondroitin achieved statistically significantly and clinically meaningful better pain scores (0-100) in studies less than 6 months than those given placebo with an absolute risk difference of 10% lower (95% confidence interval (CI), 15% to 6% lower; number needed to treat (NNT) = 5 (95% CI, 3 to 8; n = 8 trials) (level of evidence, low; risk of bias, high); but there was high heterogeneity between the trials (T(2) = 0.07; I(2) = 70%, which was not easily explained by differences in risk of bias or study sample size). In studies longer than 6 months, the absolute risk difference for pain was 9% lower (95% CI 18% lower to 0%); n = 6 trials; T(2) = 0.18; I(2) = 83% ), again with low level of evidence.For the Western Ontario and McMaster Universities Osteoarthritis Index Minimal Clinically Important Improvement (WOMAC MCII Pain subscale) outcome, a reduction in knee pain by 20% was achieved by 53/100 in the chondroitin group versus 47/100 in the placebo group, an absolute risk difference of 6% (95% CI 1% to 11%), (RR 1.12, 95% CI 1.01 to 1.24; T(2) = 0.00; I(2) = 0%) (n = 2 trials, 1253 participants; level of evidence, high; risk of bias, low).Differences in Lequesne's index (composite of pain,function and disability) statistically significantly favoured chondroitin as compared with placebo in studies under six months, with an absolute risk difference of 8% lower (95% CI 12% to 5% lower; T(2)= 0.78; n = 7 trials) (level of evidence, moderate; risk of bias, unclear), also clinically meaningful. Loss of minimum joint space width in the chondroitin group was statistically significantly less than in the placebo group, with a relative risk difference of 4.7% less (95% CI 1.6% to 7.8% less; n = 2 trials) (level of evidence, high; risk of bias, low). Chondroitin was associated with statistically significantly lower odds of serious adverse events compared with placebo with Peto odds ratio of 0.40 (95% CI 0.19 to 0.82; n = 6 trials) (level of evidence, moderate). Chondroitin did not result in statistically significant numbers of adverse events or withdrawals due to adverse events compared with placebo or another drug. Adverse events were reported in a limited fashion, with some studies providing data and others not.Comparisons of chondroitin taken alone or in combination with glucosamine or another supplement showed a statistically significant reduction in pain (0-100) when compared with placebo or an active control, with an absolute risk difference of 10% lower (95% CI 14% to 5% lower); NNT = 4 (95% CI 3 to 6); T(2) = 0.33; I(2) = 91%; n = 17 trials) (level of evidence, low). For physical function, chondroitin in combination with glucosamine or another supplement showed no statistically significant difference from placebo or an active control, with an absolute risk difference of 1% lower (95% CI 6% lower to 3% higher with T(2) = 0.04; n = 5 trials) (level of evidence, moderate). Differences in Lequesne's index statistically significantly favoured chondroitin as compared with placebo, with an absolute risk difference of 8% lower (95% CI, 12% to 4% lower; T(2) = 0.12; n = 10 trials) (level of evidence, moderate). Chondroitin in combination with glucosamine did not result in statistically significant differen
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Cohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771
Farrar, J. T., Young, J. P., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001) · Pain · doi:10.1016/s0304-3959(01)00349-9 · Cited by 5,808
Dworkin, R. H., Turk, D. C., Wyrwich, K. W., Beaton, D., Cleeland, C. S., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Kerns, R. D., Ader, D. N., et al. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.005 · Cited by 3,471
Hochberg, M. C., Altman, R. D., April, K. T., Benkhalti, M., Guyatt, G., McGowan, J., Towheed, T., Welch, V., Wells, G., & Tugwell, P. (2012) · Arthritis Care & Research · doi:10.1002/acr.21596 · Cited by 3,068
Altman, R., Alarcón, G., Appelrouth, D., Bloch, D., Borenstein, D., Brandt, K., Brown, C., Cooke, T. D., Daniel, W., Feldman, D., et al. (1991) · Arthritis & Rheumatism · doi:10.1002/art.1780340502 · Cited by 2,632
Breivik, H., Borchgrevink, P. C., Allen, S. M., Rosseland, L. A., Romundstad, L., Breivik Hals, E. K., Kvarstein, G., & Stubhaug, A. (2008) · British Journal of Anaesthesia · doi:10.1093/bja/aen103 · Cited by 2,108
Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update
(2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200009)43:9<1905::aid-anr1>3.0.co;2-p · Cited by 1,875
Validity of four pain intensity rating scales
Ferreira-Valente, M. A., Pais-Ribeiro, J. L., & Jensen, M. P. (2011) · Pain · doi:10.1016/j.pain.2011.07.005 · Cited by 1,872
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis
Clegg, D. O., Reda, D. J., Harris, C. L., Klein, M. A., O'Dell, J. R., Hooper, M. M., Bradley, J. D., Bingham, C. O., Weisman, M. H., Jackson, C. G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052771 · Cited by 1,329
Altman, R., Alarcon, G., Appelrouth, D., Bloch, D., Borenstein, D., Brandt, K., Brown, C., Cooke, T. D., Daniel, W., Gray, R., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780331101 · Cited by 1,132
Tubach, F., Ravaud, P., Baron, G., Falissard, B., Logeart, I., Bellamy, N., Bombardier, C., Felson, D., Hochberg, M., van der Heijde, D., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.022905 · Cited by 1,094
The epidemiology of osteoarthritis
Johnson, V. L., & Hunter, D. J. (2014) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2014.01.004 · Cited by 1,020
Kelly, A.-M. (2001) · Emergency Medicine Journal · doi:10.1136/emj.18.3.205 · Cited by 969
van Saase, J. L., van Romunde, L. K., Cats, A., Vandenbroucke, J. P., & Valkenburg, H. A. (1989) · Annals of the Rheumatic Diseases · doi:10.1136/ard.48.4.271 · Cited by 867
Pham, T., van der Heijde, D., Altman, R. D., Anderson, J. J., Bellamy, N., Hochberg, M., Simon, L., Strand, V, Woodworth, T., & Dougados, M. (2004) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2004.02.001 · Cited by 849
McAlindon, T. E., LaValley, M. P., Gulin, J. P., & Felson, D. T. (2000) · JAMA · doi:10.1001/jama.283.11.1469 · Cited by 849
Exercise for osteoarthritis of the knee
Fransen, M., McConnell, S., Harmer, A. R., Van der Esch, M., Simic, M., & Bennell, K. L. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004376.pub3 · Cited by 800
Intraarticular corticosteroid for treatment of osteoarthritis of the knee
Bellamy, N., Campbell, J., Welch, V., Gee, T. L., Bourne, R., & Wells, G. A. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005328.pub2 · Cited by 762
Viscosupplementation for the treatment of osteoarthritis of the knee
Bellamy, N., Campbell, J., Welch, V., Gee, T. L., Bourne, R., & Wells, G. A. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005321.pub2 · Cited by 755
Exercise for osteoarthritis of the knee
Fransen, M., & McConnell, S. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004376.pub2 · Cited by 751
Pavelká, K., Gatterová, J., Olejarová, M., Machacek, S., Giacovelli, G., & Rovati, L. C. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2113 · Cited by 683
Glucosamine therapy for treating osteoarthritis
Towheed, T., Maxwell, L., Anastassiades, T. P., Shea, B., Houpt, J., Welch, V., Hochberg, M. C., & Wells, G. A. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002946.pub2 · Cited by 659
Self-citationEPIDEMIOLOGY OF HIP AND KNEE OSTEOARTRRITIS1
FELSON, D. T. (1988) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036019 · Cited by 630
Kelly, A. (1998) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.1998.tb02667.x · Cited by 626
Wandel, S., Juni, P., Tendal, B., Nuesch, E., Villiger, P. M., Welton, N. J., Reichenbach, S., & Trelle, S. (2010) · BMJ · doi:10.1136/bmj.c4675 · Cited by 578
Pendleton, A., Arden, N., Dougados, M., Doherty, M., Bannwarth, B., Bijlsma, J. W. J., Cluzeau, F., Cooper, C., Dieppe, P. A., Günther, K.-P., et al. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.12.936 · Cited by 575
Acetaminophen for osteoarthritis
Towheed, T., Maxwell, L., Judd, M., Catton, M., Hochberg, M. C., & Wells, G. A. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004257.pub2 · Cited by 563
Self-citationQuintana, J. M., Escobar, A., Bilbao, A., Arostegui, I., Lafuente, I., & Vidaurreta, I. (2005) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2005.06.012 · Cited by 510
The epidemiology of knee osteoarthritis: Results from the framingham osteoarthritis study
Felson, D. T. (1990) · Seminars in Arthritis and Rheumatism · doi:10.1016/0049-0172(90)90046-i · Cited by 478
Escobar, A., Quintana, J. M., Bilbao, A., Aróstegui, I., Lafuente, I., & Vidaurreta, I. (2007) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2006.09.001 · Cited by 468
The algofunctional indices for hip and knee osteoarthritis.
Lequesne, M. G. (1997) · PubMed · Cited by 428
Richy, F., Bruyere, O., Ethgen, O., Cucherat, M., Henrotin, Y., & Reginster, J.-Y. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.13.1514 · Cited by 368
Dougados, M., Nguyen, M., Berdah, L., Mazi�res, B., Vignon, E., Lequesne, M., & for the ECHODIAH Investigators Study Group (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200111)44:11<2539::aid-art434>3.0.co;2-t · Cited by 321
Meta-analysis: Chondroitin for Osteoarthritis of the Knee or Hip
Reichenbach, S., Sterchi, R., Scherer, M., Trelle, S., Bürgi, E., Bürgi, U., Dieppe, P. A., & Jüni, P. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-8-200704170-00009 · Cited by 316
Bayesian Approaches to Clinical Trials and Health-Care Evaluation
Best, M. A. (2005) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/j.1467-985x.2004.00347_17.x · Cited by 303
Herrero‐Beaumont, G., Ivorra, J. A. R., del Carmen Trabado, M., Blanco, F. J., Benito, P., Martín‐Mola, E., Paulino, J., Marenco, J. L., Porto, A., Laffon, A., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22371 · Cited by 287
Kahan, A., Uebelhart, D., De Vathaire, F., Delmas, P. D., & Reginster, J. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24255 · Cited by 267
Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: A randomized, controlled trial
Michel, B. A., Stucki, G., Frey, D., De Vathaire, F., Vignon, E., Bruehlmann, P., & Uebelhart, D. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20867 · Cited by 261
Sawitzke, A. D., Shi, H., Finco, M. F., Dunlop, D. D., Harris, C. L., Singer, N. G., Bradley, J. D., Silver, D., Jackson, C. G., Lane, N. E., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.120469 · Cited by 255
Sawitzke, A. D., Shi, H., Finco, M. F., Dunlop, D. D., Bingham, C. O., Harris, C. L., Singer, N. G., Bradley, J. D., Silver, D., Jackson, C. G., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23973 · Cited by 251
April, K. T., Bisaillon, J., Welch, V., Maxwell, L. J., Jüni, P., Rutjes, A., Husni, M., Vincent, J., Hindi, T. E., Wells, G., et al. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005522.pub2 · Cited by 223
Self-citationUebelhart, D., Malaise, M., Marcolongo, R., DeVathaire, F., Piperno, M., Mailleux, E., Fioravanti, A., Matoso, L., & Vignon, E. (2004) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2004.01.004 · Cited by 217
NUTRACEUTICALS AS THERAPEUTIC AGENTS IN OSTEOARTHRITIS
Deal, C. L., & Moskowitz, R. W. (1999) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70074-0 · Cited by 209
A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis.
Leeb, B. F., Schweitzer, H., Karin, M., & Smolen, J. S. (2000) · PubMed · Cited by 206
Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study
Uebelhart, D., Thonar, E. J.-M. A., Delmas, P. D., Chantraine, A., & Vignon, E. (1998) · Osteoarthritis and Cartilage · doi:10.1016/s1063-4584(98)80011-3 · Cited by 196
Wildi, L. M., Raynauld, J.-P., Martel-Pelletier, J., Beaulieu, A., Bessette, L., Morin, F., Abram, F., Dorais, M., & Pelletier, J.-P. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.140848 · Cited by 196
Clinical Versus Statistical Significance in the Assessment of Pain Relief☆☆☆★
Todd, K. H. (1996) · Annals of Emergency Medicine · doi:10.1016/s0196-0644(96)70226-3 · Cited by 190
Arthroscopic debridement for knee osteoarthritis
Laupattarakasem, W., Laopaiboon, M., Laupattarakasem, P., & Sumananont, C. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005118.pub2 · Cited by 190
Dougados, M., Leclaire, P., van der Heijde, D., Bloch, D. A., Bellamy, N., & Altman, R. D. (2000) · Osteoarthritis and Cartilage · doi:10.1053/joca.2000.0361 · Cited by 186
Morreale, P., Manopulo, R., Galati, M., Boccanera, L., Saponati, G., & Bocchi, L. (1996) · PubMed · Cited by 182
What Is Clinically Meaningful: Outcome Measures in Pain Clinical Trials
Farrar, J. T. (2000) · The Clinical Journal of Pain · doi:10.1097/00002508-200006001-00018 · Cited by 162
Effect of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta-analysis
Lee, Y. H., Woo, J.-H., Choi, S. J., Ji, J. D., & Song, G. G. (2010) · Rheumatology International · doi:10.1007/s00296-009-0969-5 · Cited by 162
Philippi, A. F., Leffler, C. T., Leffler, S. G., Mosure, J. C., & Kim, P. D. (1999) · Military Medicine · doi:10.1093/milmed/164.2.85 · Cited by 160
McAlindon, T., Formica, M., LaValley, M., Lehmer, M., & Kabbara, K. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.06.023 · Cited by 158
Bucsi, L., & Poór, G. (1998) · Osteoarthritis and Cartilage · doi:10.1016/s1063-4584(98)80009-5 · Cited by 153
Hochberg, M. C. (2010) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2010.02.016 · Cited by 136
Abadie, E., Ethgen, D. J., Avouac, B. P., Bouvenot, G., Branco, J., Bruyère, O., Calvo, G., Devogelaer, J.-P., Dreiser, R.-L., Herrero‐Beaumont, G., et al. (2004) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2004.01.006 · Cited by 131
Gabay, C., Medinger-Sadowski, C., Gascon, D., Kolo, F. C., & Finckh, A. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30574 · Cited by 129
Effect of Glucosamine Sulfate on Hip Osteoarthritis
Rozendaal, R. M., Koes, B. W., van Osch, G. J. V. M., Uitterlinden, E. J., Garling, E. H., Willemsen, S. P., Ginai, A. Z., Verhaar, J. A. N., Weinans, H., & Bierma‐Zeinstra, S. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-4-200802190-00005 · Cited by 128
Mazières, B., Hucher, M., Zaïm, M., & Garnero, P. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.059899 · Cited by 124
Bourgeois, P., Chalès, G., Dehais, J., et al. (1998) · Osteoarthritis and Cartilage · doi:10.1016/s1063-4584(98)80008-3 · Cited by 123
Das, A., & Hammad, T. A. (2000) · Osteoarthritis and Cartilage · doi:10.1053/joca.1999.0308 · Cited by 121
Verbruggen, G., Goemaere, S., & Veys, E. M. (1998) · Osteoarthritis and Cartilage · doi:10.1016/s1063-4584(98)80010-1 · Cited by 118
Disease-Modifying Therapies for Osteoarthritis: Current Status
Fajardo, M., & Cesare, P. E. D. (2005) · Drugs & Aging · doi:10.2165/00002512-200522020-00005 · Cited by 107
Verbruggen, G., Goemaere, S., & Veys, E. M. (2002) · Clinical Rheumatology · doi:10.1007/s10067-002-8290-7 · Cited by 106
Lapane, K. L., Sands, M., Yang, S., McAlindon, T. E., & Eaton, C. B. (2011) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2011.10.005 · Cited by 90
Messier, S. P., Mihalko, S. L., Loeser, R. F., Legault, C., Jolla, J., Pfruender, J., Prosser, B. L., Adrian, A. L., & Williamson, J. D. (2007) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2007.04.016 · Cited by 87
Kanzaki, N., Saito, K., Maeda, A., Kitagawa, Y., Kiso, Y., Watanabe, K., Tomonaga, A., Nagaoka, I., & Yamaguchi, H. (2011) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.4660 · Cited by 71
Costs of osteoarthritis: estimates from a geographically defined population.
Gabriel, S. E., Cs, C., & Wm, O. (1995) · PubMed · Cited by 68
Magrans-Courtney, T., Wilborn, C., Rasmussen, C. J., Ferreira, M. P., Greenwood, L. D., Campbell, B. I., Kerksick, C. M., Nassar, E., Li, R., Iosia, M., et al. (2011) · Journal of the International Society of Sports Nutrition · doi:10.1186/1550-2783-8-8 · Cited by 64
Möller, I., Pérez, M., Monfort, J., Benito, P., Cuevas, J., Perna, C., Doménech, G., Herrero, M., Montell, E., & Vergés, J. (2010) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2010.01.018 · Cited by 61
Railhac, J.-J., Zaïm, M., Saurel, A.-S., Vial, J., & Fournié, B. (2012) · Clinical Rheumatology · doi:10.1007/s10067-012-2022-4 · Cited by 56
Serum keratan sulfate is a promising marker of early articular cartilage breakdown
Wakitani, S., Nawata, M., Kawaguchi, A., Okabe, T., Takaoka, K., Tsuchiya, T., Nakaoka, R., Masuda, H., & Miyazaki, K. (2007) · Lara D. Veeken · doi:10.1093/rheumatology/kem220 · Cited by 54
Cordoba, F., & Nimni, M. E. (2003) · Osteoarthritis and Cartilage · doi:10.1016/s1063-4584(02)00351-5 · Cited by 47
PDR for Nutritional Supplements
Ernst, E. K. (2001) · Focus on Alternative and Complementary Therapies · doi:10.1111/j.2042-7166.2001.tb03175.x · Cited by 43
Chondroitin sulfate in erosive osteoarthritis of the hands.
Rovetta, G., Monteforte, P., Molfetta, G., & Balestra, V. (2002) · PubMed · Cited by 40
Potential effects of chondroitin sulfate on joint swelling: a GAIT report
Hochberg, M. C., & Clegg, D. O. (2008) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2008.06.024 · Cited by 38
Published meta-analyses of pharmacological therapies for osteoarthritis
Towheed, T. (2002) · Osteoarthritis and Cartilage · doi:10.1053/joca.2002.0841 · Cited by 37
Fardellone, P., Zaïm, M., Saurel, A.-S., & Maheu, E. (2013) · The Open Rheumatology Journal · doi:10.2174/1874312901307010001 · Cited by 37
[Anti-arthrosis treatments: efficacy and tolerance of chondroitin sulfates (CS 4&6)].
Conrozier, T. (1998) · PubMed · Cited by 33
Nakasone, Y., WATABE, K., Watanabe, K., Tomonaga, A., Nagaoka, I., Yamamoto, T., & Yamaguchi, H. (2011) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2011.298 · Cited by 32
Maillefert, J.-F., Nguyen, M., Guéguen, A., Berdah, L., Lequesne, M., Mazières, B., Vignon, E. P., & Dougados, M. (2002) · Lara D. Veeken · doi:10.1093/rheumatology/41.2.148 · Cited by 28
Mazières, B., Loyau, G., Menkes, C. J., Valat, J. P., Dreiser, R.-L., Charlot, J., & Masounabe-Puyanne, A. (1992) · PubMed · Cited by 27
Glucosamine and Chondroitin in Osteoarthritis
Rayman, M. P., & Callaghan, A. (2006) · Wiley eBooks · doi:10.1002/9780470775011.ch10 · Cited by 4
En artrosis, glucosamina y condroitín, solos o asociados, tienen el mismo efecto que placebo
Márquez, M. C. V., López, I. F., & Camacho, J. C. D. (2011) · Farmacéuticos de Atención Primaria · doi:10.1016/s2172-3761(11)70042-5 · Cited by 1
(1988) · PubMed
Cited by
Hunter, D. J., & Bierma-Zeinstra, S. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30417-9 · Cited by 4,795
Bruyère, O., Honvo, G., Veronese, N., Arden, N. K., Branco, J., Curtis, E. M., Al-Daghri, N. M., Herrero-Beaumont, G., Martel-Pelletier, J., Pelletier, J.-P., et al. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.04.008 · Cited by 695
Animal models of osteoarthritis: classification, update, and measurement of outcomes
Kuyinu, E. L., Narayanan, G., Nair, L. S., & Laurencin, C. T. (2016) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-016-0346-5 · Cited by 583
2018 update of the EULAR recommendations for the management of hand osteoarthritis
Kloppenburg, M., Kroon, F. P., Blanco, F. J., Doherty, M., Dziedzic, K. S., Greibrokk, E., Haugen, I. K., Herrero-Beaumont, G., Jonsson, H., Kjeken, I., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213826 · Cited by 489
Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis
Liu, X., Machado, G. C., Eyles, J. P., Ravi, V., & Hunter, D. J. (2018) · British Journal of Sports Medicine · doi:10.1136/bjsports-2016-097333 · Cited by 298
Metadata
- Authors
- Singh, J. A., Noorbaloochi, S., MacDonald, R., & Maxwell, L. J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2015-01-28
- Volume
- 2016
- Issue
- 4
- Pages
- CD005614-CD005614
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1546820319
- Cited by
- 260
- References
- 87
- FWCI
- 19.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.